Comparison
While CJC-1295 is used in research to chronically elevate endogenous growth hormone and IGF-1 levels, enabling studies of body composition, metabolic, and anti-aging effects of prolonged GH exposure10, PT-141 is FDA-approved for treatment of hypoactive sexual desire disorder in premenopausal women and is studied for sexual dysfunction in other populations, increasing sexual desire via CNS melanocortin pathways42101.
While CJC-1295 works as a tetrasubstituted 29-amino-acid analog of GHRH(1–29) that acts as a potent agonist at the GHRH receptor and, in its DAC form, covalently binds serum albumin to extend half-life from minutes to days, resulting in sustained pulsatile GH and IGF-1 increase1082, PT-141 is the synthetic melanocortin receptor agonist bremelanotide, an analog of α-MSH that activates central MC3R and MC4R to modulate neuronal circuits governing sexual desire and arousal3242101.
CJC-1295 is 29 amino acids long, whereas PT-141 is shorter as it has a length of 7 amino acids. CJC-1295 is made up of a sequence of Tyrosine, Alanine, Aspartic acid, Alanine, Isoleucine, Phenylalanine, Threonine, Glutamine, Serine, Tyrosine, Arginine, Lysine, Valine, Leucine, Alanine, Glutamine, Leucine, Serine, Alanine, Arginine, Lysine, Leucine, Leucine, Glutamine, Aspartic acid, Isoleucine, Leucine, Serine, Arginine. PT-141 is made up of a sequence of sequence data not available in the current dataset.
CJC-1295
GHRH
PT-141
POMC